Janux Therapeutics (JANX) Competitors $27.22 +1.46 (+5.67%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. TGTX, NUVL, LNTH, RYTM, AXSM, TLX, CRSP, PCVX, CYTK, and MTSRShould you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Janux Therapeutics vs. Its Competitors TG Therapeutics Nuvalent Lantheus Rhythm Pharmaceuticals Axsome Therapeutics Telix Pharmaceuticals CRISPR Therapeutics Vaxcyte Cytokinetics Metsera Janux Therapeutics (NASDAQ:JANX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations. Do institutionals and insiders believe in JANX or TGTX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by company insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend JANX or TGTX? Janux Therapeutics presently has a consensus price target of $91.89, indicating a potential upside of 237.58%. TG Therapeutics has a consensus price target of $43.80, indicating a potential upside of 11.96%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Janux Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to JANX or TGTX? In the previous week, TG Therapeutics had 4 more articles in the media than Janux Therapeutics. MarketBeat recorded 10 mentions for TG Therapeutics and 6 mentions for Janux Therapeutics. TG Therapeutics' average media sentiment score of 1.05 beat Janux Therapeutics' score of 0.57 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is JANX or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to Janux Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat Janux Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -9.29% -8.89% TG Therapeutics 10.13%18.88%7.05% Which has more volatility & risk, JANX or TGTX? Janux Therapeutics has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Which has higher earnings and valuation, JANX or TGTX? TG Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10.59M152.09-$68.99M-$1.36-20.01TG Therapeutics$386.39M16.07$23.38M$0.24163.00 SummaryTG Therapeutics beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition Export to ExcelMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-20.0220.3528.6119.64Price / Sales152.09304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book1.407.718.185.63Net Income-$68.99M-$55.11M$3.23B$257.73M7 Day Performance6.79%0.68%-0.25%0.07%1 Month Performance15.29%8.22%5.40%8.32%1 Year Performance-41.31%-2.64%26.35%13.78% Janux Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.6808 of 5 stars$27.22+5.7%$91.89+237.6%-40.7%$1.61B$10.59M-20.0230TGTXTG Therapeutics3.6141 of 5 stars$38.92+5.0%$43.80+12.5%+78.5%$6.18B$329M162.17290Positive NewsNUVLNuvalent3.302 of 5 stars$84.59+4.5%$119.60+41.4%+1.8%$6.07BN/A-19.2740LNTHLantheus4.6203 of 5 stars$83.06+2.2%$131.20+58.0%-34.0%$5.75B$1.53B23.60700Positive NewsGap DownRYTMRhythm Pharmaceuticals3.1441 of 5 stars$89.15+2.8%$91.00+2.1%+72.2%$5.67B$130.13M-31.73140Analyst RevisionAXSMAxsome Therapeutics4.6921 of 5 stars$112.33+3.1%$172.33+53.4%+33.0%$5.53B$385.69M-19.47380Positive NewsAnalyst RevisionTLXTelix PharmaceuticalsN/A$15.57-2.5%$22.33+43.4%N/A$5.27B$783.21M0.00N/ANews CoverageAnalyst RevisionCRSPCRISPR Therapeutics3.232 of 5 stars$56.42-0.7%$71.75+27.2%-8.2%$4.87B$37.31M-12.48460Analyst RevisionPCVXVaxcyte1.8147 of 5 stars$36.38+1.3%$136.50+275.2%-58.1%$4.69BN/A-9.12160News CoveragePositive NewsCYTKCytokinetics4.0095 of 5 stars$38.58+4.2%$70.92+83.8%-33.8%$4.61B$18.47M-7.29250Insider TradeMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081 Related Companies and Tools Related Companies TGTX Competitors NUVL Competitors LNTH Competitors RYTM Competitors AXSM Competitors TLX Competitors CRSP Competitors PCVX Competitors CYTK Competitors MTSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JANX Stock Alerts